Research
Hormonal
Body Mass Index (BMI) is a primary mediator for the protective effect of physical activity on endometrial cancer, as adjusting for BMI eliminates the association, whereas it has limited effect on other cancer types.
For endometrial cancer prevention, maintaining a healthy BMI is likely the most critical factor, as the independent benefit of exercise appears to be mediated by weight. However, for other cancers like colon and breast, exercise provides protection even after accounting for BMI. Do not skip exercise thinking you are 'thin enough' to be safe from all cancers.
WeakQualifiesHIGH confidence
Adjustment for body mass index eliminated the association with endometrial cancer but had limited effect on other cancer types.
Why this rating
Large pooled cohort, sensitivity analysis.
Source
Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk
Charles E. Matthews et al. · Journal of Clinical Oncology · 2019
DOI 10.1200/jco.19.02407
cohort · n=755459Cited 288×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Engaging in 7.5-15 MET hours/week of leisure-time physical activity significantly lowers the risk of seven specific cancer types (colon, breast, endometrial, kidney, myeloma, liver, and non-Hodgkin lymphoma) compared to no activity.Weak
- Higher levels of physical activity beyond the recommended 15 MET hours/week do not provide additional cancer risk reduction for curvilinear cancers (kidney, gastric, liver, non-Hodgkin lymphoma), whereas linear cancers (breast, colon, endometrial) continue to show reduced risk with higher activity.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →